Page 1 of Clinical Trials for MK-0646, 20 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Active, not recruiting
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
Last Updated: October 6, 2011
Condition(s): Non Small Cell Lung Cancer
2
Completed
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Last Updated: January 13, 2010
Condition(s): Neuroendocrine Tumors; Metastatic Neuroendocrine Tumors
3
Active, not recruiting
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Last Updated: May 16, 2012
Condition(s): Pancreatic Cancer; Pancreatic Adenocarcinoma
4
Active, not recruiting
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Last Updated: June 22, 2011
Condition(s): Lung Cancer
5
Completed
Phase I Dose Escalation Trial of MK0646 in Advanced Solid Tumors and Multiple Myeloma (0646-001)(COMPLETED)
Last Updated: September 10, 2010
Condition(s): Solid Tumor; Multiple Myeloma
6
Withdrawn
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
Last Updated: December 2, 2011
Condition(s): Metastatic Colorectal Cancer
7
Active, not recruiting
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Last Updated: February 14, 2012
Condition(s): Breast Cancer
8
Completed
Infusion of MK0646 in Subjects With Advanced Solid Tumors
Last Updated: July 2, 2009
Condition(s): Advanced Solid Tumors
9
Recruiting
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Last Updated: May 10, 2012
Condition(s): Neoplasms Malignant
10
Completed
Study of MK0646 in Patients With Solid Tumors
Last Updated: August 31, 2009
Condition(s): Neoplasm
11
Completed
Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004 AM9)
Last Updated: April 9, 2012
Condition(s): Metastatic Colorectal Cancer
12
Completed
A Study of Dalotuzumab (MK0646) in Breast Cancer Patients
Last Updated: March 1, 2010
Condition(s): Breast Cancer
13
Completed
Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)
Last Updated: December 20, 2010
Condition(s): Colorectal Cancer
14
Not yet recruiting
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Last Updated: October 28, 2010
Condition(s): Lung Cancer
15
Recruiting
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Last Updated: May 11, 2012
Condition(s): Breast Cancer
16
Completed
A Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (0646-007)
Last Updated: April 24, 2012
Condition(s): Carcinoma, Non-small-cell Lung
17
Completed
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Last Updated: March 27, 2012
Condition(s): Carcinoma, Non-small Cell Lung
18
Active, not recruiting
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Last Updated: May 22, 2012
Condition(s): Breast Cancer
19
Completed
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Last Updated: December 17, 2010
Condition(s): Neoplasms
20
Not yet recruiting
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
Last Updated: May 22, 2012
Condition(s): Breast Neoplasms

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=MK-0646

Page 1 of Clinical Trials for MK-0646, 20 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About